- $1.59bn
- $1.30bn
- $184.42m
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare
U.S. STOCKS ON THE MOVE-NetEase, Werewolf Therapeutics, JP Morgan
U.S. STOCKS ON THE MOVE-Ubiquiti, BJ's Wholesale, Arbutus
U.S. STOCKS ON THE MOVE-Gold miners, Ross Stores, Stoke Therapeutics
J.P. Morgan resumes coverage on Stoke Therapeutics with 'overweight'; shares rise
U.S. RESEARCH ROUNDUP-Health Catalyst, Nektar Therapeutics, TIC Solutions
Stoke Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Stoke Therapeutics Q2 revenue falls 33% on lower collaboration, licensing income
Brief: Stoke Therapeutics Announces Completion Of Enrollment Of 162 Patients Into The Phase 3 Emperor Study Of Zorevunersen, An Investigational Medicine For The Treatment Of Dravet Syndrome
Brief: Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics Q1 revenue falls but beats estimates
Brief: Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Air Products, Chevron, Fedex
Health Rounds: Protein related to Parkinson's linked to faster Alzheimer's progression in women
Brief: Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002
Brief: Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen
Brief: Stoke Therapeutics And Biogen Present Data That Further Support The Disease-Modifying Potential Of Zorevunersen
Brief: Biogen And Stoke Therapeutics Present Data That Further Support The Disease-Modifying Potential Of Zorevunersen
Brief: Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)